University of Pittsburgh Physical Activity and Weight Management Research Center
Pittsburgh, Pennsylvania, 15261, United States
NCT Number: NCT03946228
Using a multi-method sleep assessment approach, the purpose of this study is to examine the bidirectional relationship between sleep and sedentary behavior in the context of a randomized trial investigating the impact of sedentary behavior reduction on blood pressure.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15261, United States
Disturbed sleep, most notably insomnia and obstructive sleep apnea (OSA), is highly prevalent and associated with increased risk for elevated blood pressure (BP) and cardiovascular disease. Unfortunately, despite the substantial public health burden of disturbed sleep, standard treatments are often limited by poor adherence, inadequate availability, and/or significant side effects. As such, identification of alternative approaches to mitigate disturbed sleep is greatly needed. In contrast to increasing engagement in exercise, we propose that reducing sedentary behavior (SED), or time spent sitting, is a novel and feasible approach to reduce sleep disturbance. We also propose that the presence of disturbed sleep during the intervention could blunt the adherence to attempted SED reduction and impact its cardiovascular health benefits. Therefore, the goal of this ancillary study is to test the hypotheses that SED reduction will improve sleep and that the presence of baseline sleep disturbance will reduce the effectiveness of SED reduction efforts. We will test this hypothesis by adding comprehensive sleep assessments to an ongoing randomized clinical trial (NCT03307343) that is examining the effect of SED reduction on BP. In this parent trial, 300 desk workers with elevated BP are randomized to a 3-month multicomponent behavioral intervention aimed at replacing 2-4 hr/day of SED with light-intensity activity or a 3-month no-contact control condition.
Anticipating the ability to enroll 150 participants from the remaining sample of the parent trial (estimated N~210), we will assess sleep at baseline and post-intervention using 7 nights of wrist-worn actigraphy and 1 night of home-based polysomnography (PSG), yielding objective measures of sleep quality (WASO), total sleep time (TST), OSA severity (apnea-hypopnea index [AHI]), and sleep depth (slow-wave sleep [SWS]. These data will allow us to efficiently address the following specific aims:
Aim 1: To evaluate the effect of a 3-month SED reduction intervention on objective measures of sleep quality, depth, duration, and OSA severity.
Hypothesis: Participants randomized to the SED reduction intervention will have greater reduction than control participants in actigraphy-assessed WASO (primary outcome [hypothesis 1.1]), PSG-assessed AHI and SWS, and greater increase in actigraphy-assessed TST (secondary outcomes [hypothesis 1.2]).
Aim 2: To examine the effect of baseline disturbed sleep on SED reduction and BP improvement.
Hypothesis: Intervention-induced reductions in SED (hypothesis 2.1) and BP (hypothesis 2.2) will be smaller among individuals with disturbed sleep (e.g., elevated WASO or AHI) at baseline.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
Time frame: 3 months
Primary outcome for Aim 1: actigraphy-assessed wake after sleep onset, averaged over 7 nights
Time frame: 3 months
Primary outcome for Aim 2: SED, assessed via activPAL inclinometer, averaged over 7 days
Time frame: 3 months
Primary outcome for Aim 2: resting SBP, measured via oscillometric device following a 10-minute rest averaged over two separate occasions
Time frame: 3 months
Secondary outcome for Aim 1: actigraphy-assessed TST, averaged over 7 nights
Time frame: 3 months
Secondary outcome for Aim 1: polysomnography-assessed AHI, assessed over 1 night of home-based recording
Time frame: 3 months
Secondary outcome for Aim 1: polysomnography-assessed slow-wave sleep, assessed over 1 night of home-based recording
Time frame: 3 months
Secondary outcome for Aim 2: blood pressure, assessed by an ambulatory monitor during a workday and overnight for 24 hours total
Time frame: 3 months
Secondary outcome for Aim 2: carotid-femoral and carotid-radial PWV, assessed via tonometry following a 10-minute rest
Time frame: 3 months
Self-reported sleep patterns will be assessed via a daily diary; mean and measures of variability will be obtained from 7 nights of data
Time frame: 3 months
The ESS, a measure of daytime sleepiness, will be administered at baseline and 3 months; total score will be used
Time frame: 3 months
The ISI, a measure of insomnia symptom severity, will be administered at baseline and 3 months; total score will be used
Time frame: 3 months
The 10-item version of the FOSQ, a measure of daytime dysfunction due to poor sleep, will be administered at baseline and 3 months; total score will be used
Time frame: 3 months
The PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-related Impairment Scale, a measure of daytime impairment, will be administered at baseline and 3 months; total score will be used
Time frame: 3 months
PSQI will be administered at baseline and 3 months; global score and 3 factors (sleep efficiency, perceived sleep quality, daily disturbances) will be used
Time frame: 3 months
Actigraphic sleep patterns will be assessed with the Actiwatch Spectrum Plus; mean and measures of variability will be obtained from 7 nights of data
Time frame: 3 months
Polysomnography will be performed in the participant's home at baseline and 3 months
Time frame: 3 months
Weight will be measured by digital scale at baseline and 3 months
Time frame: 3 months
Glucose will be measured from a fasting blood draw at baseline and 3 months
Time frame: 3 months
Insulin will be measured from a fasting blood draw at baseline and 3 months
Time frame: 3 months
Physical activity will be assessed via waist-worn ActiGraph GT3X accelerometer at baseline and 3 months
University of Pittsburgh
Other
Acronym: RESET-SLEEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05276362
Apnea, Dyssomnias
Menlo Park, California, United States
View Trial DetailsNCT06994104
Behavior, Behavior, Addictive
Istanbul, Marmara, Turkey (Türkiye)
View Trial DetailsNCT05974709
Behavior, Behavioral Symptoms
Çankırı, Turkey (Türkiye)
View Trial DetailsNCT03673397
Behavior, Behavioral Symptoms
Sankt Gallen, Switzerland
View Trial Details